Theravance Biopharma (NASDAQ:TBPH) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. Other research analysts have also recently issued reports about the company. Leerink Partners cut Theravance Biopharma from […]
More Stories
Justin Charles Guichard Buys 7,364 Shares of Brookfield Real Assets Income Fund Inc. (NYSE:RA) Stock
Brookfield Real Assets Income Fund Inc. (NYSE:RA – Get Free Report) Portfolio Manager Justin Charles Guichard purchased 7,364 shares of...
Deal W. Hudson Sells 2,500 Shares of Atlanticus Holdings Co. (NASDAQ:ATLC) Stock
Atlanticus Holdings Co. (NASDAQ:ATLC – Get Free Report) Director Deal W. Hudson sold 2,500 shares of Atlanticus stock in a...
Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the company’s stock in...
Steve Ladd Huffman Sells 14,000 Shares of Reddit, Inc. (NYSE:RDDT) Stock
Reddit, Inc. (NYSE:RDDT – Get Free Report) CEO Steve Ladd Huffman sold 14,000 shares of the business’s stock in a...
Full House Resorts, Inc. (NASDAQ:FLL) CEO Sells $59,506.59 in Stock
Full House Resorts, Inc. (NASDAQ:FLL – Get Free Report) CEO Daniel R. Lee sold 11,737 shares of the company’s stock...
Royal Bank of Canada (TSE:RY) Senior Officer Sells C$24,817.82 in Stock
Royal Bank of Canada (TSE:RY – Get Free Report) (NYSE:RY) Senior Officer Erica Lesley Nielsen sold 148 shares of the...